Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies

NCT03098160 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.

NCT NCT03098160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03098160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies
Lead sponsor
Threshold Pharmaceuticals
Phase
Phase 1
Overall status
Unknown status
Start date
May 10, 2017
Completion date
April 30, 2019
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, pancreatic cancer, prostate cancer, squamous cell carcinoma of the head and neck